Globus Medical (NYSE:GMED) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Globus Medical (NYSE:GMED) from a buy rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the company. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday. Wells Fargo & Company lifted their price objective on Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group cut their price objective on Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday. Truist Financial reduced their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Finally, Royal Bank Of Canada lowered their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.92.

Globus Medical Stock Down 13.2%

Shares of Globus Medical stock opened at $70.67 on Friday. Globus Medical has a twelve month low of $70.39 and a twelve month high of $101.40. The company’s 50 day moving average is $77.20 and its 200 day moving average is $83.18. The company has a market cap of $9.49 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.14 and a beta of 0.98.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.51%. The business had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. During the same quarter in the previous year, the firm posted $1.18 EPS. The firm’s revenue was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts expect that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Activity at Globus Medical

In related news, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James R. Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 60,000 shares of company stock worth $4,838,400. 18.38% of the stock is owned by company insiders.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its holdings in Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP lifted its position in Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Globus Medical by 14.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock valued at $133,731,000 after purchasing an additional 225,534 shares in the last quarter. Finally, Boston Trust Walden Corp grew its holdings in Globus Medical by 4.4% during the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock valued at $123,071,000 after purchasing an additional 69,782 shares during the period. Institutional investors own 95.16% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical